Robert Clark
Direktor/Vorstandsmitglied bei INCANNEX HEALTHCARE INC.
Vermögen: 230 000 $ am 30.04.2024
Profil
Robert Bruce Clark currently works at Incannex Healthcare, Inc., as Independent Non-Executive Director from 2022 and Novo Nordisk, Inc., as Vice President-Regulatory Affairs from 2012.
Mr. Clark also formerly worked at Pfizer Inc., as Head-United States Regulatory Strategy from 1992 to 2021.
Mr. Clark received his graduate degree from New York Medical College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
INCANNEX HEALTHCARE INC.
0,63% | 21.12.2023 | 100 000 ( 0,63% ) | 230 000 $ | 30.04.2024 |
Aktive Positionen von Robert Clark
| Unternehmen | Position | Beginn |
|---|---|---|
| INCANNEX HEALTHCARE INC. | Direktor/Vorstandsmitglied | 17.08.2022 |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | General Counsel | 01.01.2012 |
Ehemalige bekannte Positionen von Robert Clark
| Unternehmen | Position | Ende |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01.01.2021 |
Ausbildung von Robert Clark
| New York Medical College | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| INCANNEX HEALTHCARE INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
